Spravato® is a form of ketamine, specifically esketamine, which differs from traditional ketamine in its formulation and administration. While ketamine can be administered through intravenous infusion, Intra muscular or sublingual, Spravato® is administered as a nasal spray. Spravato® is FDA-approved for treatment-resistant depression, whereas ketamine is often used "off-label" for a broader range of conditions.

Ketamine and Spravato® are administered using different methods, tailored to their formulations and clinical applications : Ketamine can be administered through Intravenous (IV) Infusion, Intramuscular (IM) Injection or via Sublingual, and Spravato® (Esketamine) is a Intranasal Spray.

The number of sessions required for ketamine or Spravato® treatment can vary based on individual response, the severity of symptoms, and treatment goals. Here’s a general overview:

1-Initial Phase: Patients usually start with 2 sessions per week for the first 4 weeks. This intensive phase is designed to rapidly stabilize the patient.

2-Maintenance Phase: After the initial phase, the frequency may be reduced to once a week or every other week, depending on the patient’s response and clinical judgment.

Treatments often require ongoing evaluation to adjust the frequency and duration of sessions based on the patient's improvement and any side effects experienced. Regular follow-up appointments are crucial to monitor progress and make necessary adjustments.

Each treatment session typically lasts around two hours, depending on the type of treatment and individual response. The session usually includes an initial administration period followed by a monitored observation period of about two hours to ensure safety and to monitor for side effects. The total duration of the visit may vary slightly based on the patient's response and clinic protocols.

Some insurance plans may cover Spravato (nasal spray ketamine) for treatment-resistant depression and suicidal ideation. We collaborate with insurance providers, so some patients may only need to pay their usual copay for Spravato treatments.

Alongside Spravato, we provide intramuscular and sublingual ketamine treatments. However, because ketamine is used “off-label” for these treatments, insurance generally does not cover them. The cost for sublingual (oral) and intramuscular ketamine sessions typically ranges from $350 to $550 per session.

Yes, there are several contraindications for using Ketamine or Spravato®. These treatments may not be suitable for individuals with certain medical or psychiatric conditions. Some contraindications include:

1. Uncontrolled high blood pressure: Both Ketamine and Spravato® can elevate blood pressure, so they are not recommended for patients with uncontrolled hypertension.

2. History of aneurysms or vascular conditions: Due to the potential increase in blood pressure, individuals with a history of aneurysms or other vascular issues may be at higher risk.

3. Severe liver disease: High doses or long-term use of Ketamine may affect liver function, so caution is advised for patients with severe liver conditions.

4. Substance abuse history: Ketamine is a controlled substance, so individuals with a history of substance abuse or dependency may not be ideal candidates.

5. Certain psychiatric disorders: Patients with a history of psychosis, including schizophrenia, may not be suitable for Ketamine or Spravato® as these treatments could exacerbate symptoms.

6. Pregnancy or breastfeeding: There is limited research on the safety of Ketamine and Spravato® during pregnancy or breastfeeding, so they are generally not recommended in these cases.

Before starting treatment, a thorough evaluation by a healthcare professional is necessary to determine if either option is appropriate.

No, it is not safe to drive home immediately after a Ketamine or Spravato® treatment. Both treatments can cause side effects such as drowsiness, dizziness, or dissociation, which can impair your ability to drive safely. After treatment, it’s recommended that patients arrange for transportation or have someone else drive them home.

When undergoing treatment with Ketamine or Spravato®, potential side effects may vary depending on the individual, dosage, and method of administration. Common side effects include:

1. Dissociation: A temporary feeling of detachment from reality, often described as feeling spaced out or disconnected from surroundings.

2. Nausea and vomiting: Some individuals may experience gastrointestinal discomfort during or after treatment.

3. Increased blood pressure: Both Ketamine and Spravato® can cause a temporary rise in blood pressure, particularly during the treatment session.

4. Drowsiness or sedation: Many patients feel sleepy or fatigued after treatment and may need time to rest before resuming normal activities.

5. Dizziness or lightheadedness: A common side effect that can persist for a few hours after treatment.

6. Headaches: Some patients report mild to moderate headaches following treatment sessions.

7. Anxiety or agitation: In some cases, patients may feel anxious or restless, especially during the dissociative effects of the medication.

8. Nasal discomfort (with Spravato®): Spravato® is administered as a nasal spray, which may cause temporary irritation, discomfort, or a runny nose.

These side effects are generally short-lived and resolve after the treatment session. However, a we will closely monitor for any significant or persistent adverse reactions. It’s important to discuss your full medical history with your provider to minimize risks and ensure the safest treatment approach.